SG3 Management’s Sage Therapeutics SAGE Stock Holding History

SG3 Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-52,500	Closed	-$1.7M	–	416
2022 Q2	$1.7M	Buy	52,500 +15,000	+40%	+$503K	0.2%	96
2022 Q1	$1.24M	Sell	37,500 -69,500	-65%	-$2.61M	0.03%	406
2021 Q4	$4.55M	Hold	107,000	–	–	0.09%	193
2021 Q3	$4.74M	Sell	107,000 -7,900	-7%	-$362K	0.14%	148
2021 Q2	$6.53M	Sell	114,900 -49,700	-30%	-$3.51M	0.23%	102
2021 Q1	$12.3M	Buy	+164,600	New	+$13.5M	0.31%	70

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG3 Management's SAGE Position: Q3 2022 in Review

SG3 Management sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 16,000 shares — an estimated $517K sold.

SG3 Management first reported a position in SAGE in Q3 2021 and held it in 4 quarters. The position peaked at $1.81M in Q4 2021. 201 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

SG3 Management reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
SG3 Management sold 16,000 Sage Therapeutics shares in Q3 2022, an estimated $517K.
SG3 Management first reported a position in Sage Therapeutics in Q3 2021 and held it in 4 quarters.
SG3 Management's Sage Therapeutics position peaked at $1.81M in Q4 2021.
201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.